Feasibility and early experience of a novel multidisciplinary alcohol-associated liver disease clinic

被引:39
|
作者
Mellinger, Jessica L. [1 ]
Winder, Gerald Scott [2 ,7 ]
Fernandez, Anne C. [2 ,3 ]
Klevering, Kristin [3 ,4 ]
Johnson, Amanda [1 ]
Asefah, Haila [1 ]
Figueroa, Mary [5 ]
Buchanan, Jack [6 ]
Blow, Fred [2 ,3 ]
Lok, Anna S. F. [1 ]
机构
[1] Michigan Med, Dept Internal Med, Ann Arbor, MI USA
[2] Michigan Med, Dept Psychiat, Ann Arbor, MI USA
[3] Univ Michigan, Addict Treatment Serv, Michigan Med, Ann Arbor, MI 48109 USA
[4] Michigan Med, Dept Social Work, Ann Arbor, MI USA
[5] Univ Michigan, Sch Publ Hlth, Ann Arbor, MI 48109 USA
[6] Univ Michigan, Med Sch, Ann Arbor, MI USA
[7] Michigan Med, Dept Surg, Ann Arbor, MI USA
关键词
Alcoholic cirrhosis; Psychiatry; Addiction; Alcohol use disorder; Quality; VALIDATION; DISORDER;
D O I
10.1016/j.jsat.2021.108396
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Background: Alcohol cessation improves mortality in alcohol-associated liver disease (ALD), but access to treatment is limited. To address this gap, implementation and early feasibility and outcomes of a multidisciplinary ALD clinic are described. Methods: The clinic comprised a hepatologist, psychiatrist, psychologist, nurse, and social worker. Patients included those with alcohol-associated cirrhosis or acute alcoholic hepatitis who were not in the transplant evaluation process, who had less than 6 months' sobriety and willingness to engage in alcohol use treatment. Psychosocial metrics in addition to routine hepatic function labs were collected. Treatment plans were tailored based on patient preferences and needs after multidisciplinary discussion. Results: 89 patients were referred from both inpatient and outpatient settings, with 51 seen during the initial year. 38 remained active in clinic (4 died, 6 discharged, 3 moved to transplant clinic). 55% were women, 88% were white, 61% had private insurance. 49% had alcoholic hepatitis. 71% were decompensated. 80% had severe alcohol use disorder (AUD) and 84% had at least 1 comorbid psychiatric or substance use disorder. 63% chose one-on-one AUD treatment, 57% were prescribed relapse prevention medications. Mean MELD-Na score improved from baseline of 14 (SD 6.6) to 11.3 at 6 months (p=0.01). Hospital utilization significantly declined when comparing 6 months before to 6 months after initial visit (emergency department visits: 0.51 to 0.20 per person-month; inpatient admission: 0.34 to 0.14 per person-month; (beta=-0.89, 95% CI-1.18 to -0.60). Conclusions: A multidisciplinary ALD clinic was feasible with encouraging early outcomes. Further research should explore ways to expand this model and increase clinic capacity.
引用
收藏
页数:7
相关论文
共 50 条
  • [21] Liver transplantation for alcohol-associated hepatitis
    Durkin, Claire
    Bittermann, Therese
    CURRENT OPINION IN ORGAN TRANSPLANTATION, 2023, 28 (02) : 85 - 94
  • [22] Alcohol-Associated Liver Diseases Spectrum, Nomenclature, and Definitions
    Shasthry, Saggere Muralikrishna
    Sarin, Shiv Kumar
    CLINICS IN LIVER DISEASE, 2024, 28 (04) : 621 - 631
  • [23] The urgent need for multidisciplinaryapproaches in managing alcohol-associated liver disease: Editorial on "The prognostic impact of psychiatric intervention on alcohol-associated liver disease: The UK Biobank cohort study"
    Kim, Soon Sun
    Cheong, Jae Youn
    CLINICAL AND MOLECULAR HEPATOLOGY, 2025, 31 (01)
  • [24] Reducing the Global Burden of Alcohol-Associated Liver Disease: A Blueprint for Action
    Asrani, Sumeet K.
    Mellinger, Jessica
    Arab, Juan P.
    Shah, Vijay H.
    HEPATOLOGY, 2021, 73 (05) : 2039 - 2050
  • [25] Selective use of liver transplantation for severe alcohol-associated hepatitis
    Ayyala-Somayajula, Divya
    Han, Hyosun
    Terrault, Norah A.
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2020, 14 (03) : 175 - 184
  • [26] Integrated and collaborative care across the spectrum of alcohol-associated liver disease and alcohol use disorder
    Haque, Lamia Y.
    Leggio, Lorenzo
    HEPATOLOGY, 2024, 80 (06) : 1408 - 1423
  • [27] Role of the ghrelin system in alcohol use disorder and alcohol-associated liver disease: A narrative review
    Kharbanda, Kusum K.
    Farokhnia, Mehdi
    Deschaine, Sara L.
    Bhargava, Raghav
    Rodriguez-Flores, Marcela
    Casey, Carol A.
    Goldstone, Anthony P.
    Jerlhag, Elisabet
    Leggio, Lorenzo
    Rasineni, Karuna
    ALCOHOL-CLINICAL AND EXPERIMENTAL RESEARCH, 2022, 46 (12): : 2149 - 2159
  • [28] Treating Alcohol Use Disorder in Patients with Alcohol-Associated Liver Disease: Controversies in Pharmacological Therapy
    Tarli, Claudia
    Mirijello, Antonio
    Addolorato, Giovanni
    SEMINARS IN LIVER DISEASE, 2022, 42 (02) : 138 - 150
  • [29] Prevention and control of risk factors in metabolic and alcohol-associated steatotic liver disease
    Desalegn, Hailemichael
    Farias, Renata
    Hudson, David
    Idalsoaga, Francisco
    Cabrera, Daniel
    Diaz, Luis Antonio
    Arab, Juan Pablo
    METABOLISM AND TARGET ORGAN DAMAGE, 2024, 4 (03):
  • [30] Elevated stearoyl-CoA desaturase 1 activity is associated with alcohol-associated liver disease
    Klepp, T. D.
    Sloan, M. E.
    Soundararajan, Soundarya
    Ramsden, C. E.
    Cinar, R.
    Schwandt, M. L.
    Diazgranados, N.
    Vatsalya, V.
    Ramchandani, V. A.
    ALCOHOL, 2022, 102 : 51 - 57